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Letters to the editor
Hepatocellular carcinoma in a
patient with Gaucher disease on
enzyme supplementation therapy
Gaucher disease is an autosomal recessive disorder character-
ized by the deficiency of the lysosomal enzyme glucocerebrosi-
dase. Accumulation of glucocerebroside occurs in macrophages
leading to hepatosplenomegaly and bone marrow infiltration
with consequently cytopenia and bone disease (type I Gauch-
er). Neurological disturbances are rare and have a rapidly fatal
(infantile, type II) or chronic progressive (juvenile, type III)
course [1]. In 1991 the first series appeared about enzyme
supplementation therapy [2], followed by the experience from
other centers [3]. Over the last years more than 1500 patients
received or are receiving enzyme replacement therapy. This
therapy consists of alglucerase or imiglucerase injections.
Alglucerase is purified from a pool of placental tissue collected
from several donors and therefore human chorionic gonado-
trophin (hCG) is present in this product. The recently developed
imiglucerase is produced using recombinant DNA technology.
Increased risk of malignancy in patients with Gaucher dis-
ease has been observed [4]. It has been hypothesized that this
might be due to a defective immune surveillance due to chronic
stimulation as consequence of accumulation of glucocerebro-
side in macrophages, T-cell dysfunction resulting from high
levels of ferritin or from a factor released from monocytes.
Hematological malignancies are predominant (myeloma, lym-
phatic leukemia, lymphoma), solid tumors are rare. Hepato-
cellular carcinoma (HCC) was reported once in a type I
Gaucher disease patient with cirrhosis and hepatitis B, in
which both diseases were suggested as possible causative
factors for the malignancy [5]. We report a case of HCC in a
62-year-old Caucasian male, known with Gaucher disease
type I. His disease was characterized by hepatosplenomegaly
and bone and joint.destructions. In 1988 severe leuco- and
thrombopenia developed due to hypersplenism which resolved
after splenectomy. Because of progressive bone destruction
resulting in a serious mobility impairment, he was offered
therapy with alglucerase. He has received weekly 15 U/kg
from April 1995 till November 1996. No side-effects occurred
and he responded well, as judged by a decrease in liver volume.
In December 1996, ultrasound and computed tomography of
upper abdomen, performed because of persistent pain in the
right upper abdomen, revealed an echodense lesion in the left
liver lobe. Diagnostic laparotomy revealed metastatic lesions
in peritoneum, omentum and tumor in the left liver lobe.
Histological examination showed HCC cells in all specimens.
At the moment of HCC diagnosis, laboratory test showed
normal liver synthesis (ATIII 92%, cholinesterase 2100 IU,
albumin 41 g/l), negative hepatitis B serology, normal immu-
noglobulin electrophoresis and elevated a-foetoprotein (AFP)
of 89.000 ug/1.
There were no known predisposing factors for HCC. Retro-
spective analysis of blood samples, taken every six months,
revealed that the AFP level prior to the start of alglucerase
therapy was normal (3 ug/1). Six months later it was slightly
elevated (11 ug/1) and showed further rise (101, 36500, 83628
ug/1) in following samples. The increase in AFP during the
supplementation therapy suggests a possible relation with the
alglucerase treatment and thus simultaneous long-term expo-
sure to hCG. In alglucerase, hCG is partially deglycosylated
during the production process and cleared at a higher rate than
native hCG. However, its in vivo biological activity is yet
unclear. HCC's often express hCG. Occurrence of HCC dur-
ing pregnancy has been reported and oral contraceptives are a
risk factor for its development. It could be speculated that
exogenous administered hCG might serve directly as growth
factor in inducing HCC or play an indirect role by modifica-
tion of other hormones. Imiglucerase as a recombinant DNA
product does not contain hCG. Another option is that occur-
rence of HCC in this patient is merely due to prolonged
compromized immune surveillance secondary to macrophage
dysfunction. The fact that HCC has never been reported in
Gaucher disease patients without risk factors and that enzyme
supplementation therapy is new, justifies attention for the
potential carcinogenic effect of hCG alglucerase therapy. It
might be relevant to check AFP levels during this therapy in
order to evaluate whether other patients also develop a HCC
and, if so, to reveal this at an early stage.
Z. Erjavec,1 C. E. M. Hollak2 & E. G. E. de Vries3
Departments of iHematology, z Medical Oncology, Uni-
versity Hospital Groningen; 2Department of Hematology,
Academic Medical Center, Amsterdam, The Netherlands
References
1. Beutler E, Grabowski G. Gaucher disease. In: Scriver CRBA, Sly
WS, Valle D (eds): The Metabolic Basis of Inherited Disease. New
York: McGraw-Hill 1995; 2641.
2. Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy
for inherited enzyme deficiency-macrophage-targeted glucoccrc-
bridase for Gaucher's disease. N Engl J Med 1991; 324: 1464.
3. Hollak CE, Aerts JM, Goudsmit R ct al. Individualised low-dose
alglucerase therapy for type I Gaucher's disease. Lancet 1995; 345:
1474.
4. Shiran A, Brenner B, Laor A.Tatarsky I. Increased risk of cancer
in patients with Gaucher disease. Cancer 1993; 72: 219.
5. Breidem-Langen CM, Buchsel K, Brambs HJ et al. Koinzidenz
eines Morbus Gaucher mit primarem hepatocellularem Karzinom.
Laben-Magen-Darm 1991; 21: 126, 129.
Cost comparison between PAV and
ICE treatment with peripheral blood
progenitor cells (PBPC) reinfusion in
small-cell lung cancer (SCLC)
High-dose chemotherapy with reinfusion of autologous hemato-
poietic progenitors has improved the prognosis of patients with
lymphomas [1]. For patients with small cell lung cancer (SCLC),
early intensification with ICE (ifosfamide, carboplatinum, eto-
poside) resulted in a median survival of 19 months for patients
with limited disease (LD) and 10 months for patients with
extensive disease (ED) [2]. The standard PAV regimen (cispla-
244
tinum, adriamycine and etoposide = VP16) results in a median
survival of 12 months (15 for LD and 10 for ED patients) [3].
The costs of the two regimens were compared in four
patients treated with PAV (two men and two women, one LD
and three ED, median age: 60 years, range 48-70) and four
patients treated with ICE and PBPC reinfusion (three men and
one woman, two LD and two ED, median age: 61 years, range
41-63).
The chemotherapy regimens were as follows: PAV (plati-
num: 30 mg/m2, days 1-3; adriamycin: 40 mg/m2, day 1 and
VP16: 100 mg/m2, days 1-3) was administered every 28 days
for six cycles. The ICE regimen included two phases: PBPC
mobilization with epirubicine (150 mg/m2 over two days)
followed by filgrastim (5 jig/kg/day) until leucaphereses com-
pletion. ICE consisted in ifosphamide (2.5 g/m2/day, con-
tinuous infusion for four days), carboplatin (300 mg/m2/day)
and etoposide (300 mg/m2/day) days 1-4, followed by reinfusion
of PBPC and filgrastim (5 ug/kg/day) until leucocyte recovery.
Three cycles were administered at monthly intervals.
Cost identification was carried out as follows: physician,
nurse, secretarial and administrative times were estimated for
each patient specifically according to the data provided by
multiple sources. Blood, platelets transfusions and drugs were
valued at cost price; laboratory tests, paramedical services and
external consultations at price charged. Overhead was extracted
from the cost accounting system.
The hospital stay was 36 ± 5 days in the PAV group and
59 ± 2 days in the ICE group. The break down of costs per
treatment phase, per nature of expenses and the comparison
between treatments is shown in Table 1. Intensification chemo-
therapy with PBPC reinfusion for treatment of SCLC was 2.4
times more expensive than traditional PAV treatment, due to
longer hospital stay, more febrile neutropenia, higher drug
acquisition costs, and greater platelets and red cells trans-
fusion needs.
This cost comparison study was based on too few patients
to analyze their survival. The recent multicentric phase II trial
with sequential ICE and other recently published results using
growth factors [4] suggest that intensifying chemotherapy in
SCLC patients may increase the number of long survivors.
Table 1. Break down of costs by treatment phase and type of resources.
PAV group
(71=4)
Cost per phase (mean ± SEM)
Pre-treatment
Chemotherapy
Febrile neutropenia
Outpatient visits (one
month)
Cost per type of resources
(mean ± SEM)
Physician time
Nursing time
Administrative time
Laboratory tests
Other paraclinic tests
Drugs
Blood products
Other direct charges
Indirect charges
Total cost (CHF)
0
34,883 ± 5,601
9,341 + 7,645
5,498 ± 748
4,478 ± 389
14,779 ± 1,718
1,076 ±99
4,801 ±818
5,880 ± 1,163
7,496 ± 373
330 ± 270
2,018 ±237
8,865 ± 1,319
49,721 ±4,617
ICE group
(«=4)
641 ± 0
85,138 + 3,438
31,667 ±4.136
3,353 ± 752
5,978 ± 55
34,986 ± 505
1,124 ±50
17,490 ± 1,607
7,844 ± 426
26,150 ±3,438
9,358 ± 687
3,654 ± 119
14,216 ±437
120,798 +4,401
ICE/
PAV
ratio
_
2.4
3.4
0.6
1.3
2.4
1.0
3.6
1.3
3.5
28.4
1.8
1.6
2.4
However, in order to remain within the cost-benefit ratio usually
accepted for medical interventions, the difference in cost be-
tween the two treatments should not exceed $50,000/life-year
saved or quality-adjusted life-year saved (QALY) [5]. In our
setting, this implies that survival would have to increase by a
full year.
High-dose chemotherapy followed by PBPC in SCLC pa-
tients is presently evaluated in a randomized phase III study
supported by the EBMT. Cost analysis and cost/benefit ratios
will undoubtly help delineating the clinical role of this approach.
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A specific approval procedure for
prescribing albumin: Impact on
consumption in a cancer treatment
institution
Albumin solution is a natural colloid solution which is mainly
indicated for hypovolemia and osmotic pressure disorders.
Alternative, equally effective treatments, such as crystalloid or
synthetic colloid solutions are available at a lower cost [1].
Until 1994, our 500-bed cancer treatment institution was
devoid of a system for channeling albumin consumption. In
January 1995, the hospital's executive committee entrusted the
Transfusion and Hemosurveillance Safety Committee (THSC)
with the responsibility of rationalizing albumin consumption.
The hospital hemobiologist, a THSC member in charge of
transfusion, proposed institute-specific guidelines defining
very limited indications for albumin based on current knowl-
edge [2, 3]. These guidelines were validated by three other
physicians in the institute and by an outside expert and were
then approved by all THSC members and the institute Medical
Affairs Manager. A letter was sent to all physicians informing
them of these recommendations in March 1995. Subsequently,
albumin prescriptions were systematically vetted, according
to these recommendations, by the hemobiologist who then
contacted the prescriber to check and validate each prescrip-
tion before delivery of albumin.
Results of the rationalization procedure are presented in
Table 1. Between 1994, the baseline year before implementation
